PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial
Abstract
Authors
J. Braverman D.S. Dhanda O. Moshkovich S. Lanar M. Miera A.E. Williams R. Murphy J. Devlen K. Hege T.B. Campbell